Last reviewed · How we verify
Chronic kidney disease
Approved treatments
- Dapaglifozin · MedImmune LLC
- DAPA · Astrazeneca Ab
- Farxiga · AstraZeneca
Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine. - Forxiga · AstraZeneca Turkey
- Farxiga · AstraZeneca
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic kidney disease patent landscape — cliff calendar, originator estates, attackable patents
- Chronic kidney disease treatment landscape brief
- Chronic kidney disease treatment updates RSS
Frequently asked questions about Chronic kidney disease
What drugs treat Chronic kidney disease?
Tracked treatments include Dapaglifozin, DAPA, Farxiga, Forxiga.
What is the treatment for Chronic kidney disease?
Standard treatment for Chronic kidney disease includes Dapaglifozin, DAPA, Farxiga, Forxiga. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic kidney disease patent cliff · Chronic kidney disease CI report
- Treatment: Dapaglifozin · MedImmune LLC
- Treatment: DAPA · Astrazeneca Ab
- Treatment: Farxiga · AstraZeneca
- Treatment: Forxiga · AstraZeneca Turkey
- Treatment: Farxiga · AstraZeneca
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing